✦ LIBER ✦

Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro

✍ Scribed by Yoshiro Saikawa; Tetsuro Kubota; Tsong-Hong Kuo; Suguru Kase; Toshiharu Furukawa; Hirokazu Tanino; Kyuya Ishibiki; Masaki Kitajima

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 466 KB
Volume: 54
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.2930540209

No coin nor oath required. For personal study only.

✦ Synopsis

The synergistic antitumor activity of mitomycin C (MMC) and cisplatin (DDP) against the gastric cancer cell lines MKN-28 and MKN-45 was assessed in vitro using the MTT assay. The synergism of the two agents was evaluated in terms of the interaction index (1.1.). The sequence of MMC followed by DDP showed higher antitumor activity than the reverse sequence against MKN-28 and MKN-45, and the intracellular concentration of platinum was significantly increased in MKN-45 by preincubation with MMC, suggesting that MMC modulates cellular permeability to DDP or the ability of DDP to intercalate DNA. Since these two antitumor agents show different types of toxicity clinically, i.e., myelotoxicity by MMC and nephrotoxicity by DDP, this combination chemotherapy could be advantageous by providing synergistic antitumor activity without increased toxicity.

📜 SIMILAR VOLUMES

Synergistic antitumor activity of combin

Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice

✍ Yoshiro Saikawa; Dr. Tetsuro Kubota; Tsong-Hong Kuo; Toshiharu Furukawa; Suguru 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB

A new combined cancer chemotherapy regimen of mitomycin C (MMC) and cisplatin (DDP) showed synergistic antitumor activity against human gastric cancer xenografts St-40 and SC-1-NU in BALB/c nu/nu mice. The drugs were administered intraperitoneally at doses of 2 or 4 mg/kg for MMC and 3 or 6 mg/kg fo

Synergistic antiproliferative activity o

Synergistic antiproliferative activity of human fibroblast interferon in combination with alpha-difluoromethylornithine against human gastric cancer cells In vitro

✍ Shunichiro Kubota 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 426 KB 👁 2 views

Comparison of the antitumor activity of

Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro

✍ A. Harstrick; J. Casper; R. Guba; H. Wilke; H. Poliwoda; H. J. Schmoll 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB 👁 1 views

The in vitro and in vivo Antitumor Activ

The in vitro and in vivo Antitumor Activity of Vitamin C: K3 Combinations Against Prostate Cancer

✍ James M. Jamison; Jacques Gilloteaux; Henryk S. Taper; Pedro Buc Calderon; Laszl 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 8 KB 👁 2 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.

Antitumor activity of cis-diamminedichlo

Antitumor activity of cis-diamminedichloroplatinum (II) depends on its time × concentration product against human gastric cancer cell lines in vitro

✍ Naoto Kurihara; Tetsuro Kubota; Yasunori Hoshiya; Yoshihide Otani; Koichiro Kuma 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB

## Abstract A pharmacodynamic study of cisplatin (DDP) was conducted using the gastric cancer cell lines MKN‐45 and MKN‐74 in vitro. Ten thousand tumor cells were incubated with 0.4–500 μg/ml DDP for 1–25 h, followed by recovery culture for a further 48 h. At the end of incubation, cell viability w

Combination chemotherapy with mitomycin-

Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer

✍ Niell, Harvey B. ;Griffin, John P. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

The drug combination of mitomycin-C, cisplatin, and vinblastine was administered to 30 patients with stage III non-small-cell lung cancer. All patients had a performance status of 50% or greater, had evaluable disease, and had not received previous chemotherapy. The overall response rate was 37% wit